跳至主要内容
临床试验/NCT06735235
NCT06735235已完成1 期

Evaluation of Salivary Fluoride Clearance Following the Use of Three MFP-Containing Dentifrices

Procter and Gamble1 个研究点 分布在 1 个国家目标入组 27 人开始时间: 2021年7月14日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
27
试验地点
1
主要终点
area under the curve (AUC)

研究概览

简要总结

This is a single-center, four-treatment, four-period crossover study. Over the course of the study, up to thirty qualified subjects will use four (4) study treatment products, one time each according to the randomization. Subjects will brush with 1.25g of the assigned study product at each visit. Subjects will provide saliva samples at baseline and at 2, 6, 12, and 30 minutes post-treatment. The F- concentrations in each saliva sample will be determined by ion chromatography

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Be at least 18 years of age;
  • Provide written informed consent prior to study participation and be given a signed copy of the Informed Consent form;
  • Be in good general health as determined by the Investigator/Designee based on a review of their medical history;
  • Have at least 16 natural teeth;
  • Have normal salivary flow (0.3-0.6 ml/min) or deemed acceptable by the Investigator/Designee as determined in a previous screening outside of this protocol;
  • Agree not to participate in any other oral care studies for the duration of this study;
  • Agree not to change their current oral care routine except 1) to refrain from using mouth rinse and 2) to agree to use study washout product as designated (current floss users are permitted to continue to floss during this study); viii. Agree to delay elective dentistry, including dental prophylaxis, until study completion, and to report any non-study dentistry received during the course of the study;
  • Agree to refrain from eating, using breath mints, using medicated lozenges, chewing gum, brushing their teeth or drinking within 2 hours of the visit, other than small sips of water up to 30 minutes prior to the visit;
  • Agree to refrain from drinking tea or mineral water, and/or eating sardines within the 12 hours prior to the study visit; and
  • Agree to return for all scheduled visits and to follow all study procedures.

排除标准

  • Active treatment for gingivitis, periodontitis, or caries;
  • Self-reported pregnancy or nursing;
  • Smoking or tobacco chewing;
  • Sjögren syndrome or any other disease/condition causing severe xerostomia;
  • Kidney disease or renal impairment;
  • Undergoing chemotherapy or irradiation procedures;
  • Fixed orthodontic appliances that may interfere with product use;
  • Inability to undergo any study procedures; or
  • Any condition or disease, as determined by the Investigator/Designee that could be expected to interfere with examination procedures or with the subject's safe completion of the study

研究组 & 干预措施

Period 2

Other

0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)

干预措施: 250 ppm F as MFP (Drug)

Period 1

Other

0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)

干预措施: 0 ppm F (Drug)

Period 1

Other

0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)

干预措施: 250 ppm F as MFP (Drug)

Period 1

Other

0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)

干预措施: 1100 ppm as MFP (Drug)

Period 1

Other

0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)

干预措施: 2800 ppm F as MFP (Drug)

Period 2

Other

0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)

干预措施: 0 ppm F (Drug)

Period 2

Other

0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)

干预措施: 1100 ppm as MFP (Drug)

Period 2

Other

0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)

干预措施: 2800 ppm F as MFP (Drug)

Period 3

Other

0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)

干预措施: 0 ppm F (Drug)

Period 3

Other

0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)

干预措施: 250 ppm F as MFP (Drug)

Period 3

Other

0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)

干预措施: 1100 ppm as MFP (Drug)

Period 3

Other

0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)

干预措施: 2800 ppm F as MFP (Drug)

Period 4

Other

0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)

干预措施: 0 ppm F (Drug)

Period 4

Other

0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)

干预措施: 250 ppm F as MFP (Drug)

Period 4

Other

0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)

干预措施: 1100 ppm as MFP (Drug)

Period 4

Other

0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)

干预措施: 2800 ppm F as MFP (Drug)

结局指标

主要结局

area under the curve (AUC)

时间窗: 2-minutes, 6-minutes, 12-minutes, and 30-minutes

The primary endpoint will be AUC of the fluoride levels from 2 to 30 minutes. AUC will be calculated for each subject and treatment combination by integrating a 3 parameter first order decay model curve estimate (y= theta1 \* exp (-theta2.X) + theta3). For any values obtained for a timepoint that are below the detection limit, 0.5 times the detection limit will be used. The following rules will apply if a subject has missing value(s) before the AUC is calculated: * If 2 or more timepoints are missing within a period, then the AUC will be set to missing * If only 2-minute data are missing, then curve will be estimated as above * If 6-minute or 12-minute data are missing, a linear imputation between the adjacent timepoints will be used * If 30-minute data are missing, the 12-minute data will be carried forward.

次要结局

未报告次要终点

研究者

发起方
Procter and Gamble
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Salivary Fluoride Clearance | 临床试验